GenVec to Present at 26th Annual ROTH Conference

               GenVec to Present at 26th Annual ROTH Conference

PR Newswire

GAITHERSBURG, Md., March 3, 2014

GAITHERSBURG, Md., March 3, 2014 /PRNewswire/ --GenVec, Inc. (NASDAQ:GNVC)
announced today that the Company will participate in the 26th Annual ROTH
Conference being held March 9-12, 2014 in Dana Point, California. Douglas
Swirsky, President and CEO of GenVec, will present a company overview on
Monday, March 10, 2014 at 3:00 pm Pacific Daylight Time.

A webcast of Mr. Swirsky's presentation will be available both live and on
replay. The presentation will be available via webcast at A replay will also be available for 90
days following the live presentation. The live webcast and subsequent archived
replay of GenVec's presentation will also be accessible via the Investors and
Media section of the Company's web site at under "Events
& Presentations."

About GenVec

GenVec is a biopharmaceutical company working with leading companies and
organizations such as Novartis and the U.S. Government to leverage GenVec's
proprietary gene-delivery technologies to address the prevention and treatment
of significant health concerns. GenVec's lead program, in the field of
regenerative medicine, is licensed to Novartis for the development of novel
treatments for hearing loss and balance disorders. Additional information
about GenVec is available at and in the company's various
filings with the Securities and Exchange Commission.

GenVec, Inc.
Rena Cohen
(240) 632-5501

SOURCE GenVec, Inc.

Press spacebar to pause and continue. Press esc to stop.